Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: J Immunol. 2018 Aug 13;201(7):2094–2106. doi: 10.4049/jimmunol.1800578

Figure 6. Engineered immunocytokine reduces disease severity in a mouse model of colitis.

Figure 6.

(a) Schematic of the mouse colitis study. BALB/c mice (n=6 per cohort) were treated once daily for 7 days with PBS, IL-2 plus a control antibody, IL-2/JES6–1 complex, or JY3 IC. Beginning on day 8, mice were subjected to 3% DSS in their drinking water to induce colitis. Weight loss (b) and disease activity index (c) were assessed on day 15. Mice were sacrificed on day 16 and colon length (d) was measured. Data represent mean ± s.d. Statistical significance by one-way ANOVA + Dunnett’s multiple comparison post-test is indicated. The experiment was performed twice with similar results.